James L Ford
Overview
Explore the profile of James L Ford including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
339
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shemilt K, Morecroft C, Ford J, Mackridge A, Green C
Eur J Hosp Pharm
. 2019 Jun;
24(4):213-217.
PMID: 31156943
Objective: The individualised patient prescription chart, either paper or electronic, is an integral part of communication between healthcare professionals. The aim of this study is to ascertain the extent to...
2.
Madathilethu J, Roberts M, Peak M, Blair J, Prescott R, Ford J
BMJ Paediatr Open
. 2018 Apr;
2(1):e000198.
PMID: 29637186
Objectives: Children requiring cortisol replacement therapy are often prescribed hydrocortisone doses of 2.5 mg, but as this is commercially unavailable 10 mg tablets, with functional break lines, are split commonly...
3.
Richey R, Hughes C, Craig J, Shah U, Ford J, Barker C, et al.
Int J Pharm
. 2017 Jan;
518(1-2):155-166.
PMID: 28040560
This study sought to determine whether there is an evidence base for drug manipulation to obtain the required dose, a common feature of paediatric clinical practice. A systematic review of...
4.
Ghazal H, Dyas A, Ford J, Hutcheon G
Drug Dev Ind Pharm
. 2015 Aug;
41(10):1647-54.
PMID: 26288994
To accurately predict the in vivo performance of drugs from an in vitro dissolution test, the dissolution conditions used are supposed to be similar to those present in the gastrointestinal...
5.
Mohamed F, Roberts M, Seton L, Ford J, Levina M, Rajabi-Siahboomi A
Drug Dev Ind Pharm
. 2014 Feb;
41(4):623-30.
PMID: 24564797
Extended release (ER) of water-soluble drugs from hydroxypropylmethylcellulose (HPMC) matrix mini-tablets (mini-matrices) is difficult to achieve due to the large surface area to volume ratio of the mini matrices. Therefore,...
6.
Richey R, Craig J, Shah U, Nunn A, Turner M, Barker C, et al.
Int J Pharm
. 2013 Nov;
457(1):339-41.
PMID: 24216239
No abstract available.
7.
Mohamed F, Roberts M, Seton L, Ford J, Levina M, Rajabi-Siahboomi A
Drug Dev Ind Pharm
. 2013 Oct;
41(1):70-8.
PMID: 24134563
The particle size of HPMC is a critical factor that can influence drug release rate from hydrophilic matrix systems. Percolation theory is a statistical tool which is used to study...
8.
Shafiei N, Ford J, Morecroft C, Lisboa P, Taylor M, Mouzughi Y
PDA J Pharm Sci Technol
. 2013 Jul;
67(4):307-22.
PMID: 23872442
Lay Abstract: The intent of this paper is to provide proof to demonstrate if there is any operational evidence that supports the 14 transformation triggers previously identified during the theoretical...
9.
Shafiei N, Ford J, Morecroft C, Lisboa P, Taylor M
PDA J Pharm Sci Technol
. 2013 Jul;
67(4):297-306.
PMID: 23872441
Lay Abstract: The pharmaceutical industry is currently going through changes that affect the way it performs its research, manufacturing, and regulatory activities. The impact of these changes on the approaches...
10.
Shafiei N, Ford J, Morecroft C, Lisboa P, Taylor M, Mouzughi Y
PDA J Pharm Sci Technol
. 2013 Jun;
67(3):229-46.
PMID: 23752750
Lay Abstract: In this paper through conduct of an expert opinion survey the proposed quality risks carried forward from an earlier part of the research are validated and resultant quality...